Altasciences

AltasciencesAltasciences
Altasciences

Altasciences

Integrated drug development solutions for pharmaceutical and biotechnology companies, from preclinical to clinical trials.

DR 49Speed 311992Active1896Laval, Canada
Rate

About

Altasciences is a contract research organization (CRO) that offers a comprehensive, end-to-end solution for early-phase drug development. They partner with pharmaceutical and biotechnology companies to streamline the process from lead candidate selection through clinical proof of concept, aiming to accelerate the delivery of new drugs to market. Their services include preclinical safety testing, clinical pharmacology studies, bioanalysis, manufacturing, and analytical services.
Frequently asked

What does Altasciences do?

Altasciences is a contract research organization (CRO) that offers a comprehensive, end-to-end solution for early-phase drug development. They partner with pharmaceutical and biotechnology companies to streamline the process from lead candidate selection through clinical proof of concept, aiming to accelerate the delivery of new drugs to market. Their services include preclinical safety testing, clinical pharmacology studies, bioanalysis, manufacturing, and analytical services.

What is Altasciences's valuation?

StartupHub estimates Altasciences's effective valuation at $347.6M (range $197.5M to $474.0M, 22% confidence), based on comparable companies in the sector.

How much funding has Altasciences raised?

Altasciences has raised a total of $79M in funding.

Where is Altasciences headquartered?

Altasciences is headquartered in Laval, Canada.

When was Altasciences founded?

Altasciences was founded in 1992.

What industry does Altasciences operate in?

Altasciences operates in Biotech & Longevity, Drug Discovery, Clinical Trials, Contract Research Organization, Pharmaceutical Research & Development, CRO.

How many employees does Altasciences have?

Altasciences has approximately 1896 people on record.

HEADCOUNT
1896
DOMAIN RATING
49
Comments

No comments yet. Be the first to share your take.